ATE407573T1 - Verwendung von lokal verabreichten lysine zur verbesserung der vaskularen funktion - Google Patents

Verwendung von lokal verabreichten lysine zur verbesserung der vaskularen funktion

Info

Publication number
ATE407573T1
ATE407573T1 AT96938656T AT96938656T ATE407573T1 AT E407573 T1 ATE407573 T1 AT E407573T1 AT 96938656 T AT96938656 T AT 96938656T AT 96938656 T AT96938656 T AT 96938656T AT E407573 T1 ATE407573 T1 AT E407573T1
Authority
AT
Austria
Prior art keywords
lysine
topically administered
vascular function
improve vascular
restenosis
Prior art date
Application number
AT96938656T
Other languages
English (en)
Inventor
John Cooke
Victor Dzau
Gary Gibbons
Sverin Schwarzacher
Tai Lim
Alan Yeung
Original Assignee
Univ Leland Stanford Junior
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27071057&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE407573(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from US08/556,035 external-priority patent/US5891459A/en
Application filed by Univ Leland Stanford Junior filed Critical Univ Leland Stanford Junior
Application granted granted Critical
Publication of ATE407573T1 publication Critical patent/ATE407573T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A23L33/175—Amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/36—Antigestagens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0012—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044—Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0073—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen 1.14.13
    • C12N9/0075—Nitric-oxide synthase (1.14.13.39)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y114/00—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14)
    • C12Y114/13—Oxidoreductases acting on paired donors, with incorporation or reduction of molecular oxygen (1.14) with NADH or NADPH as one donor, and incorporation of one atom of oxygen (1.14.13)
    • C12Y114/13039—Nitric-oxide synthase (NADPH dependent) (1.14.13.39)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT96938656T 1995-11-09 1996-10-24 Verwendung von lokal verabreichten lysine zur verbesserung der vaskularen funktion ATE407573T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/556,035 US5891459A (en) 1993-06-11 1995-11-09 Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US08/695,792 US5852058A (en) 1993-06-11 1996-08-12 Intramural delivery of nitric oxide enhancer for inhibiting lesion formation after vascular injury

Publications (1)

Publication Number Publication Date
ATE407573T1 true ATE407573T1 (de) 2008-09-15

Family

ID=27071057

Family Applications (1)

Application Number Title Priority Date Filing Date
AT96938656T ATE407573T1 (de) 1995-11-09 1996-10-24 Verwendung von lokal verabreichten lysine zur verbesserung der vaskularen funktion

Country Status (5)

Country Link
US (1) US5852058A (de)
EP (1) EP0871376B1 (de)
JP (1) JP2000506496A (de)
AT (1) ATE407573T1 (de)
WO (1) WO1997016983A1 (de)

Families Citing this family (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5891459A (en) * 1993-06-11 1999-04-06 The Board Of Trustees Of The Leland Stanford Junior University Enhancement of vascular function by modulation of endogenous nitric oxide production or activity
US6425881B1 (en) * 1994-10-05 2002-07-30 Nitrosystems, Inc. Therapeutic mixture useful in inhibiting lesion formation after vascular injury
US20110196039A9 (en) * 1994-10-05 2011-08-11 Kaesemeyer Wayne H Controlled release arginine formulations
US6239172B1 (en) * 1997-04-10 2001-05-29 Nitrosystems, Inc. Formulations for treating disease and methods of using same
DE69637676D1 (de) * 1995-11-09 2008-10-23 Univ R Verwendung von lokal verabreichten Lysine zur VERBESSERUNG DER VASKULAREN FUNKTION
EP1041880B1 (de) * 1997-09-17 2010-01-27 Strategic Science & Technologies, LLC Verabreichung von arginin zur erwärmung von kaltem/kühlem gewebe
US7629384B2 (en) 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US7914814B2 (en) 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
AU3221599A (en) * 1998-04-03 1999-10-25 Daily Wellness Company, The Compositions comprising l-arginine, ginseng and gingko biloba for enhancing blood circulation
US6219577B1 (en) 1998-04-14 2001-04-17 Global Vascular Concepts, Inc. Iontophoresis, electroporation and combination catheters for local drug delivery to arteries and other body tissues
US6159942A (en) * 1998-06-19 2000-12-12 Bioenergy, Inc. Compositions for increasing energy in vivo
JP2002539257A (ja) * 1999-03-19 2002-11-19 イーノス・ファーマシューティカルス・インコーポレーテッド 薬剤の脳内生物学的利用率の増加
FR2791571B1 (fr) * 1999-04-02 2002-10-04 Sod Conseils Rech Applic Association inhibiteur(s) de no synthase et antioxydant(s) metabolique(s)
MXPA01001297A (es) * 1999-06-05 2004-01-29 Univ Leland Stanford Junior Metodo y composicion para inhibir la proliferacion celular, cardiovascular.
JP2004501143A (ja) 2000-06-22 2004-01-15 ニトロメド　インコーポレーテッド ニトロソ化およびニトロシル化タキサン、組成物および使用方法
AU8852301A (en) * 2000-09-01 2002-03-13 Meir S Sacks Compositions and methods for inducing vasorelaxation
US6497885B2 (en) 2000-12-22 2002-12-24 The Daily Wellness Company Method and composition for improving fertility health in female and male animals and humans
US6989164B2 (en) 2000-12-22 2006-01-24 The Daily Wellness Company Method and composition for improving male fertility health
US6706274B2 (en) * 2001-01-18 2004-03-16 Scimed Life Systems, Inc. Differential delivery of nitric oxide
US7025734B1 (en) * 2001-09-28 2006-04-11 Advanced Cardiovascular Systmes, Inc. Guidewire with chemical sensing capabilities
US7217426B1 (en) 2002-06-21 2007-05-15 Advanced Cardiovascular Systems, Inc. Coatings containing polycationic peptides for cardiovascular therapy
US7056523B1 (en) 2002-06-21 2006-06-06 Advanced Cardiovascular Systems, Inc. Implantable medical devices incorporating chemically conjugated polymers and oligomers of L-arginine
US7794743B2 (en) 2002-06-21 2010-09-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US7011842B1 (en) 2002-06-21 2006-03-14 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of making the same
US8506617B1 (en) 2002-06-21 2013-08-13 Advanced Cardiovascular Systems, Inc. Micronized peptide coated stent
US7070798B1 (en) 2002-06-21 2006-07-04 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical devices incorporating chemically-bound polymers and oligomers of L-arginine
US6994867B1 (en) 2002-06-21 2006-02-07 Advanced Cardiovascular Systems, Inc. Biocompatible carrier containing L-arginine
US7033602B1 (en) 2002-06-21 2006-04-25 Advanced Cardiovascular Systems, Inc. Polycationic peptide coatings and methods of coating implantable medical devices
US7094256B1 (en) 2002-12-16 2006-08-22 Advanced Cardiovascular Systems, Inc. Coatings for implantable medical device containing polycationic peptides
CA2557814A1 (en) * 2004-03-01 2005-09-15 Lumen Therapeutics, Llc Compositions and methods for treating diseases
WO2005102282A1 (en) 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Transdermal delivery of beneficial substances effected by a hostile biophysical environment
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
PL1819241T3 (pl) * 2004-12-08 2014-07-31 Unilever Nv Produkt spożywczy albo napój zawierający teaninę i kofeinę dla zwiększania skupienia umysłu
EP3556401A1 (de) 2005-05-27 2019-10-23 The University of North Carolina at Chapel Hill Stickoxidfreisetzende partikel für stickoxidtherapeutika und biomedizinische anwendungen
US8945655B2 (en) * 2007-07-10 2015-02-03 Conopco, Inc. Stable and consumable compositions
US20090155420A1 (en) * 2007-12-12 2009-06-18 Conopco, Inc., D/B/A Unilever Food product with stabilized non-protein amino acids
EP2300603A4 (de) * 2008-06-24 2011-08-03 Micropharma Ltd Stickoxidvorrichtung und verfahren zur wundheilung, behandlung von hauterkrankungen und mikrobiellen infektionen
EA019809B9 (ru) * 2008-11-11 2014-08-29 Юнилевер Нв Композиция черного чая
EP2445493A1 (de) 2009-06-24 2012-05-02 Strategic Science & Technologies, LLC Topische zusammensetzung mit naproxen
WO2010151240A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing ibuprofen
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
US9919072B2 (en) 2009-08-21 2018-03-20 Novan, Inc. Wound dressings, methods of using the same and methods of forming the same
WO2011022652A1 (en) 2009-08-21 2011-02-24 Novan, Inc. Topical gels
US8591876B2 (en) 2010-12-15 2013-11-26 Novan, Inc. Methods of decreasing sebum production in the skin
WO2012092523A1 (en) 2010-12-29 2012-07-05 Strategic Science & Technologies, Llc Systems and methods for treatment of allergies and other indications
CN103429247A (zh) 2010-12-29 2013-12-04 战略科学与技术有限责任公司 勃起功能障碍和其它适应症的治疗
EP2681286B1 (de) 2011-02-28 2018-08-15 Novan, Inc. Stickoxid-freisetzende s-nitrosothiol-modifizierte kieselsäureteilchen und verfahren zu ihrer herstellung
WO2014112641A1 (ja) 2013-01-21 2014-07-24 協和発酵バイオ株式会社 一酸化窒素濃度上昇剤
RU2579608C1 (ru) * 2014-09-22 2016-04-10 Александр Александрович Кролевец Способ получения нанокапсул l-аргинина и норвалина в альгинате натрия
RU2607589C2 (ru) * 2014-10-06 2017-01-10 Александр Александрович Кролевец Способ получения нанокапсул аминокислот в конжаковой камеди

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1704M (fr) * 1961-12-19 1963-02-18 Aec Chim Organ Biolog Médicament anti-allergique et anti-histaminique a base de β-alanine.
FR2122342B1 (de) * 1971-01-21 1974-08-02 Tixier Madeleine
US4029773A (en) * 1973-05-25 1977-06-14 Syntex (U.S.A.) Inc. Composition and method of treating ulcers
US4847240A (en) * 1978-01-16 1989-07-11 The Trustees Of Boston University Method of effecting cellular uptake of molecules
WO1988001872A1 (en) * 1986-09-10 1988-03-24 Dudrick Medical Research Fund I, Ltd. Method and substrate composition for treating atherosclerosis
US5032608A (en) * 1986-09-10 1991-07-16 Dudrick Stanley J Method and substrate composition for treating atherosclerosis
US4920098A (en) * 1986-09-17 1990-04-24 Baxter International Inc. Nutritional support or therapy for individuals at risk or under treatment for atherosclerotic vascular, cardiovascular, and/or thrombotic diseases
US5236413B1 (en) * 1990-05-07 1996-06-18 Andrew J Feiring Method and apparatus for inducing the permeation of medication into internal tissue
US5372807A (en) * 1990-05-14 1994-12-13 University Of Medicine And Dentistry Of New Jersey Polymers containing antifibrotic agents, compositions containing such polymers, and methods of preparation and use
US5278189A (en) * 1990-06-04 1994-01-11 Rath Matthias W Prevention and treatment of occlusive cardiovascular disease with ascorbate and substances that inhibit the binding of lipoprotein (A)
US5499971A (en) * 1990-06-15 1996-03-19 Cortrak Medical, Inc. Method for iontophoretically delivering drug adjacent to a heart
AU8074591A (en) * 1990-06-15 1992-01-07 Cortrak Medical, Inc. Drug delivery apparatus and method
AU655780B2 (en) * 1990-10-30 1995-01-12 Clintec Nutrition Company A method and composition for the protection of a metabolic recovery of ischemic cardiac tissue
US5171217A (en) * 1991-02-28 1992-12-15 Indiana University Foundation Method for delivery of smooth muscle cell inhibitors
US5318531A (en) * 1991-06-11 1994-06-07 Cordis Corporation Infusion balloon catheter
JPH05163139A (ja) * 1991-12-12 1993-06-29 Ajinomoto Co Inc 抗動脈硬化剤
WO1994016729A1 (en) * 1993-01-28 1994-08-04 Neorx Corporation Targeted nitric oxide pathway or nitric oxide synthase modulation
CA2164632A1 (en) * 1993-06-11 1994-12-22 John P. Cooke Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production or activity
US5428070A (en) * 1993-06-11 1995-06-27 The Board Of Trustees Of The Leland Stanford Junior University Treatment of vascular degenerative diseases by modulation of endogenous nitric oxide production of activity
US5482925A (en) * 1994-03-17 1996-01-09 Comedicus Incorporated Complexes of nitric oxide with cardiovascular amines as dual acting cardiovascular agents
US5576287A (en) * 1994-04-29 1996-11-19 Wake Forest University Method for treating acute renal disease and failure
US5681278A (en) * 1994-06-23 1997-10-28 Cormedics Corp. Coronary vasculature treatment method
US5569198A (en) * 1995-01-23 1996-10-29 Cortrak Medical Inc. Microporous catheter

Also Published As

Publication number Publication date
JP2000506496A (ja) 2000-05-30
EP0871376A1 (de) 1998-10-21
US5852058A (en) 1998-12-22
EP0871376B1 (de) 2008-09-10
WO1997016983A1 (en) 1997-05-15
EP0871376A4 (de) 2004-03-24

Similar Documents

Publication Publication Date Title
ATE407573T1 (de) Verwendung von lokal verabreichten lysine zur verbesserung der vaskularen funktion
MY104685A (en) Substituted thiazoles and their use as fungicides.
AU7321598A (en) Use of cholinesterase inhibitors to treat disorders of attention
ATE218336T1 (de) Verwendung von 3-benzoylphenylessigsäuren, deren estern oder amiden zur behandlung von glc1a glaukom
DE69132048T2 (de) Verwendung von Steroiden zur Inhibierung von Angiogenesis
DE69526853T2 (de) Hemmung der fortpflanzung von arterienglattmuskelzellen
ATE193443T1 (de) Verwendung eines imidazols zur herstellung eines medikamentes zur behandlung der arteriosklerose
AU6998787A (en) Transglutaminase inhibitors
DE69634951D1 (de) Topische verwendung von betulinsäure zur behandlung bösartiger melanome
GR3036691T3 (en) Dna sequences related to isolated fragile x syndrome
IL110727A0 (en) Thiadiazole and oxadiazole derivatives for treating schizophrenia and schizophreniform diseases
FI940375A0 (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
AU6335496A (en) Benzothiophene compounds
GR3034575T3 (en) Steroid nitrite ester derivatives useful as anti-inflammatory drugs
ATE119770T1 (de) Verwendung von acetyl l-carnitin zur therapeutischen behandlung von coma.
DE69636934D1 (de) Verwendung von aromatischen oder verzweigten aminosäuren zur behandlung von bewegungsstörungen
HK1014498A1 (en) Bpi-protein-products for depressed reticuloendothelial system function.
ATE180669T1 (de) Verwendung von pregnanderivaten zur behandlung von tumoren
DE59202618D1 (de) BIOTENSIDE ESTER MIT VITAMIN-D-VERBINDUNGEN; IHRE HERSTELLUNG UND AUFARBEITUNG ZU SPONTAN DISPERGIERBAREN kONZENTRATEN, SOWIE IHRE VERWENDUNG ZUR BEHANDLUNG VON TUMOREN.
DE59900286D1 (de) Verwendung von sphingosin-1-phosphat, sphingosin-1-phosphat-derivaten und/oder deren gemische zur behandlung von entzündlichen hautkrankheiten
ATE181240T1 (de) Verwendung von somatostatinanalogen zur behandlung von melanomen
ATE234613T1 (de) Verwendung von comt inhibitoren zur herstellung eines arzneimittels zur vorbeugung von diabetischen vaskulären funktionsstörungen
BG102087A (en) The use of pyrrolidine derivatives for the treatment of alcoholism
EP0330218A3 (de) Lysyl-Oxidase-Inhibitoren
FI892051A (fi) Foerfarande foer framstaellning av 5-klor-3-klorsulfonyl-2-tiofencarbonsyraestrar.

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties